We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Automatic Point-of-Care System Measures COVID-19 Antibodies Along with HbA1c, CRP, U-Albumin within 3 Minutes

By LabMedica International staff writers
Posted on 06 Oct 2020
Print article
Image: Epithod AutoDx analyzer and Epithod SARS-CoV-2 qAb antibody test kit (Photo courtesy of DxGen Corp.)
Image: Epithod AutoDx analyzer and Epithod SARS-CoV-2 qAb antibody test kit (Photo courtesy of DxGen Corp.)
A new automatic point-of-care system measures COVID-19 antibodies along with HbA1c, glycated albumin, hemoglobin, C-reactive protein and U-Albumin within just three minutes.

DxGen Corp. (Korea) has launched the Epithod AutoDx analyzer and Epithod SARS-CoV-2 qAb antibody test kit, which allows to easily test IgM/IgG antibodies to SARS-CoV-2. The Epithod SARS-CoV-2 qAb is a vitro diagnostic (IVD) test that can detect IgM and IgG antibodies produced after virus infection in human whole blood and serum/plasma. According to DxGen, the Epithod SARS-CoV-2 qAb test kit has a sensitivity and specificity of 97% and 100%, respectively at 95% confidence intervals.

The test kit is a gold nanoparticle-based immunoassay for semi-quantitative determination with the easy-to-use Epithod AutoDx analyzer. Users can put the test kit and specimen on the tray and press a button, after which the analyzer perform the entire test process automatically. A key benefit of the Epithod AutoDx analyzer is that in addition to measuring IgM/IgG antibodies to SARS-CoV-2, it can also measure various underlying diseases test markers such as HbA1c, glycated albumin, hemoglobin, C-reactive protein, U-Albumin, etc. By providing medical professionals with various and valuable diagnostic information, the Epithod system can be effectively used not only for COVID-19 diagnosis tests, but also for complication diagnosis tests and patient prognosis monitoring and treatment in various medical front lines.

"We are currently processing the FDA EUA, and we have plan to quickly add test kits such as D-dimer, COVID-19 Antigen, Influenza A/B, etc.," said Dr. Jinwoo Lee, CEO of DxGen Corp.



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more